Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › Foundation Medicine, Natera to Develop Liquid Biopsy Monitoring Assays

Foundation Medicine, Natera to Develop Liquid Biopsy Monitoring Assays

Sep 24, 2019
|
staff reporter

This article has been updated with financial and other details from a Natera regulatory filing.

NEW YORK – Foundation Medicine and Natera said today that they will jointly develop and commercialize personalized circulating tumor DNA monitoring assays for biopharmaceutical and clinical customers who order the FoundationOne CDx test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In Molecular Diagnostics

  1. MIT, 3M Receive $500K to Develop Rapid SARS-CoV-2 Antigen Diagnostic Test

  2. Helix, San Diego County Partner on COVID-19 Molecular Testing

  3. FDA Grants EUAs for Boston Medical Center, Beijing Wantai Biological Pharmacy Coronavirus Tests

  4. SARS-CoV-2 Pandemic May Promote Progress in Paper MDx

  5. Amid Interest Generated by Coronavirus Testing, IPO Window Open for Dx Firms in 2020

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.